Immune mechanisms have been shown to contribute to the process of myelodysplastic syndromes (MDS)-related bone marrow (BM) failure. The aim of this study was to evaluate the possible contribution of activated monocytes through CD40-CD40L(CD154) interactions with activated T helper cells. We demonstrated in 77 predominantly lower risk MDS patients that the CD40 receptor was expressed significantly higher on monocytes and that CD40L was expressed significantly higher on T helper cells in peripheral blood (PB) and BM. Increased levels of CD40 and CD40L were detected in the same patients. In addition, stimulation of the CD40 receptor on purified PB monocytes led to a significantly higher tumor necrosis factor alpha production in patients. Co-culture of BM mononuclear cells of 21 patients in the presence of a blocking CD40 monoclonal antibody (ch5D12) led to a significant increase in the number of colony-forming units. A correlation was seen between increased CD40 expression on monocytes with patients' age below 60 years and with the cytogenetic abnormality trisomy 8. These results demonstrate that CD40 expression on monocytes may identify a subgroup of MDS patients in whom immune-mediated hematopoietic failure is part of the disease process. As such, the CD40-CD40L-based activation of monocytes might be a target to counteract MDS-related BM failure.
Introduction
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematopoietic disorders with a variable degree of bone marrow (BM) failure and a tendency to evolve to acute leukemia. The pathogenesis of BM failure in MDS is complex and is thought to be related to a delicate interplay between intrinsic defects in the hematopoietic progenitor cells and the BM microenvironment in which these progenitor cells reside. 1 There is increasing evidence that also immune mechanisms play an important role in the pathogenesis of MDS-related pancytopenia.
Most evidence points towards a role of T lymphocytes in this process of BM failure. In vitro experiments demonstrate that autologous T lymphocytes can suppress MDS progenitor growth. 2, 3 Clonal and oligoclonal T cell expansions can be found in about half of the patients 2,4-7 and these clones have been shown to suppress hematopoiesis in vitro. 5 Compelling evidence for the effective role of T cells in the process of BM failure comes from the observation that up to 30% of low-risk MDS patients respond to immunosuppressive agents such as cyclosporine A (CsA), 8 and/or anti-thymocyte globulin (ATG) [9] [10] [11] [12] [13] [14] which mainly target activated T cells. It is not known to what extent monocytes are involved in the process of MDS-related marrow failure. Monocytes could play a pivotal role, as previous studies have shown that they are the principal cellular source of tumor necrosis factor alpha (TNF-a) production in MDS. 15 TNF-a has been implicated in the pathogenesis of MDS-related marrow failure because of its pro-apoptotic properties (reviewed by Parker et al. 16 ). However, studies by Visani et al. demonstrated that TNF-a production by MDS monocytes is unaltered. 17 Activation of monocytes/ macrophages is a crucial event for the development of the inflammatory response in vivo, because these cells are capable of synthesizing a wide array of pro-inflammatory mediators not only in response to a number of soluble factors, but also through direct interaction with other cells, such as activated T cells. The CD40-CD40L system appears to be important for this function, 18, 19 and the contribution of CD40-CD40L interactions in immune-mediated processes has been shown in several autoimmune diseases such as rheumatoid arthritis, 20, 21 inflammatory bowel disease, 22, 23 autoimmune encephalomyelitis 24 and thyroiditis. 25 To investigate a possible role of CD40-CD40L interaction in MDS, we evaluated expression of CD40 on monocytes and CD40L on T helper cells in a large group of patients with MDS. In addition, we have investigated if agonizing and antagonizing CD40 on MDS monocytes affects the production of TNF-a and affects the outgrowth of colony-forming units (CFU) in vitro. Finally, we correlated these findings to clinical and disease characteristics.
Patients, materials and methods

Patient data and samples
All sampling and handling were conducted in accordance with the guidelines of the local ethical committee of the University Hospital of Leuven, which comply with the Helsinki declaration. Samples from 85 different patients with morphologically proven MDS were used for this study. Patient characteristics are summarized in Table 1 . The samples were obtained at routine peripheral blood (PB) and BM sampling after informed consent. The majority of patients (61 of 85 patients) did not receive therapy for MDS at the time the samples were collected. Patients with concomitant or recent history (within last month) of infection were excluded from this analysis. Data on cytogenetic analysis were provided by the Center for Human Genetics of the University Hospital of Leuven and the Cytogenetic Lab of the Bordet Institute of Brussels. In addition, PB samples were obtained from 60 healthy volunteers. Donors (n ¼ 29) used in the flow cytometry studies were age matched (mean age 68, range 59-82) with the MDS patients. BM aspirates of 11 healthy young volunteers (mean age 21, range [19] [20] [21] [22] [23] [24] were also obtained to serve as control samples. Hematologic values were determined with a Sysmex XE-2100 automated Hematology Analyzer. Serum C-reactive protein (CRP) concentration was measured on an Hitachi Modular Analytics D automated analyzer with a particle-enhanced immunoturbidimetric method (CRPLX, Roche Diagnostics).
Flow cytometry
PB and BM samples were collected in sodium EDTA-coated tubes and were processed immediately. After lysis with 10:1 NH 4 Cl buffer and washing with phosphate-buffered saline (PBS, Bio-Whittaker Europe, Cambrex, Belgium), cells were immunostained with the following fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-and peridinin chlorophyll (PerCP)-conjugated monoclonal antibodies (MoAbs): anti-CD3; anti-CD4; anti-CD14; anti-CD40L; anti-CD40; anti-CD80; anti-CD86; anti-CD45 (all from Becton Dickinson, Erembodegem, Belgium). Appropriate isotype-matched negative controls were used for each sample. Cells were resuspended in PBS containing 10% human AB serum (obtained from a single donor) to block Fc receptors to avoid nonspecific binding. Cells were incubated with 10 ml of the monoclonal antibody for 30 min at 41C in the dark and subsequently washed once and resuspended in 400 ml CellFIX (Becton Dickinson). Samples were analyzed on a FACScan or FACSCanto Flowcytometer (Becton Dickinson).
To determine the phenotype of monocytes, we gated on the CD14 þ population with intermediate side scatter (SSC) and enumerated the percentage of cells in this population that was double-positive for CD14 and CD40, CD14 and CD80, and CD14 and CD86. Similarly, we gated on the population with low SSC that was CD4 and CD3 double-positive, to determine the percentage of this population that expressed CD40L.
Monocyte isolation and stimulation
PB mononuclear cells (PBMNCs) were isolated over a FicollHypaque (Lymphoprep, Nycomed Pharma, Oslo, Norway) step gradient and washed once in PBS and subsequently in magnetic cell sorting (MACS) buffer. CD14 þ cells were isolated by MACS using CD14 þ magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Isolated CD14 þ cells were enumerated using trypan blue exclusion. They were subsequently plated in Iscove's modified Dulbecco's Medium (IMDM, Gibco BRL Life Technologies, Paisley, UK) supplemented with penicillin and streptomycin (Gibco BRL Life Technologies) and 15% fetal bovine serum (FBS, StemCell Technologies, Vancouver, British Columbia, Canada) in wells of 24-well plates (Falcon Multiwell, Becton Dickinson) at a density of 3 Â 10 5 cells ml
À1
. After 1 week of culture in a humidified incubator at 371C with 5% CO 2 , the medium was replaced with fresh medium supplemented with either lipopolysaccharide (LPS, Santa Cruz Biotechnology, Heildelberg, Germany) at 1 mg ml À1 or a mixture of clone 64 (agonist anti-human CD40 monoclonal antibody, PanGenetics, Utrecht, The Netherlands) at 10 mg ml À1 , and interferon-gamma (IFN-g, Santa Cruz Biotechnology, Germany) at a final concentration of 1000 IU ml À1 . After 24 h, supernatant was harvested and stored at À201C until further analysis.
Colony-forming assay
Following the enumeration of viable cells, BMMNCs (5 Â 10 5 for MDS patients, 2.5 Â 10 5 for controls) were prepared in MethoCult H4434 media containing 30% FBS, 50 ng ml À1 stem cell factor, 10 ng ml À1 granulocyte-macrophage colony-stimulating factor, 10 ng ml À1 interleukin-3 and 3 U ml À1 erythropoietin (StemCell Technologies). From each sample, a tube without and a tube with ch5D12 (antagonist chimeric antihuman CD40 antibody, PanGenetics) at a final concentration of 10 mg ml À1 was prepared and plated in duplicate wells. Following 14 days of incubation, plates were scored using an inverted microscope. On the basis of cell number and colony morphology, we defined granulocyte-monocyte CFU (CFU-GM), and erythroid CFU, either single or clustered, as burstforming units-erythroid (BFU-E). We therefore separated our PB patient group into two, using the highest measured value of the control group (6.4%) as cut-off value. Relative frequencies were compared with w 2 -tests or Fisher's exact tests for low (below 5) frequencies. P-values represent double-sided tests. P-values below 0.05 were considered significant.
Results
Increased expression levels of CD40, CD80 and CD86 on MDS monocytes
Using flow cytometry, we analyzed the phenotype of circulating monocytes in the PB of 57 MDS patients. According to the FAB classification, 37 patients were diagnosed with refractory anemia (RA) and 20 with RA with ringed sideroblasts (RARS); according to the WHO classification 1 patient was diagnosed with RA, 30 with refractory cytopenia with multilineage dysplasia (RCMD), 1 with RARS, 19 with refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS), 3 with a 5qÀ syndrome and 3 with unclassified MDS (MDS-u). The majority did not receive any treatment for MDS prior to sample collection (37 of 57). Therapies for MDS included transfusion (n ¼ 9), growth-factors (four recombinant human erythropoietin, one recombinant human granulocyte colonystimulating factor and one combination of both of these two), iron-chelation therapy alone (n ¼ 1) or a combination of these therapies (n ¼ 4). To exclude any influence of age on the phenotype of monocytes, PB of 29 age-matched subjects served as control group. We gated on the population of CD14 þ with intermediate side-scatter characteristics to enumerate the percentage of monocytes coexpressing CD40 (see Figures 1a and b). Upon activation, monocytes express not only the CD40, but also the B7-molecule CD80, while expression of CD86 is further upregulated. 18, 19 We therefore also analyzed expression levels of CD80 and CD86.
Absolute numbers of circulating monocytes were comparable in both groups. MDS patients had significantly more circulating CD40 þ (9.9%71.1 vs 2.8%70.3, Po0.0001), CD80 þ (3.6%70.5 vs 1.7%70.2, P ¼ 0.008) and CD86 þ (73.8%73.1 vs 56.9%74.3, P ¼ 0.002) monocytes compared to age-matched control subjects (see Figure 1c) . The same observation was made in the BM of 20 patients (data not shown). We found a highly significant correlation between the percentage of CD40 þ and CD80 þ monocytes (Spearman's r ¼ 0.54, Po0.0001), indicating that both activation markers are expressed at high levels in the same patients. Expression of CD86 was variable and did not correlate significantly with either CD40 or CD80 expression levels, presumably because even in the absence of significant CD40 or CD80 expression, monocytes already express significant levels of CD86.
Increased expression of CD40L on MDS T helper cells
We also evaluated expression of CD40L (CD154) on the surface of T helper cells in the same group of patients and normal controls. CD40L was found to be significantly more expressed on T helper cells from MDS patients (4.2%70.4 vs 2.2%70.2, Po0.0001, see Figure 2b ) compared to age-matched controls. This was also found for T helper cells present in BM aspirates of MDS patients (4.8%70.8 vs 2.6%70.5, P ¼ 0.02). Furthermore, we found a correlation between expression of CD40 by monocytes and CD40L expression by T helper cells (Spearman r ¼ 0.30, P ¼ 0.03), indicating that activation of monocytes and lymphocytes occurs in the same patients.
Activation of the CD40 receptor induces higher TNF-a production in MDS
We next evaluated if TNF-a production differs when monocytes from MDS patients or healthy control donors are stimulated with an agonist anti-human CD40 antibody or LPS. We therefore isolated CD14
þ cells from PB of 18 MDS patients and 25 healthy controls. According to the FAB classification, these MDS patients were diagnosed as RA (n ¼ 12) and RARS (n ¼ 6) and as RCMD (n ¼ 10), RCMD-RS (n ¼ 6), 5qÀ syndrome (n ¼ 1) and MDS-u (n ¼ 1) according to the WHO classification. After 7 days of culture to induce maturation, CD14 þ cells were subjected for 24 h to two different stimuli to induce TNF-a production: LPS or an agonist anti-human CD40 mAb (clone 64, PanGenetics). 26 To maximize the response to the given stimulus, we used a high concentration of LPS (1 mg ml À1 ). For the same reason, we combined the agonist anti-CD40 antibody with IFN-g (final concentration 1000 IU ml À1 ), as IFN-g is known to induce transcription of the CD40 receptor. 27 The mean purity of CD14 þ isolation was 97.1% (range 91.9-99.7%) for controls and 97.2% (range 95.0-98.9%) for MDS patients. TNF-a levels of unstimulated CD14 þ cells were low (371 pg ml À1 ) in both groups. As shown in Figure 3 , LPS induced similar levels of TNFa in patients (108744 pg ml À1 ) and controls (100732 pg ml
À1
). In contrast, the agonist anti-CD40 antibody combined with IFNg induced a significantly higher TNF-a production by CD14 þ monocytes from MDS patients compared to normal controls (4817144 vs 67720 pg ml À1 , P ¼ 0.007). In identical conditions of maximum CD40 expression and stimulation, monocytes from patients thus appear to produce more TNF-a than control monocytes.
Antagonizing the CD40 receptor on monocytes leads to increased colony formation in MDS
As we demonstrated, overexpression of the CD40 receptor on monocytes and its ligand on T helper cells, and that activation of this receptor led to increased TNF-a production, we hypothesized that interference with CD40 signaling may affect hematopoietic progenitor growth in vitro. To test this hypothesis, we used an antagonist anti-CD40 mAb (ch5D12, PanGenetics) to inhibit CD40 signaling. 22 We plated BMMNCs of 21 patients in the presence or absence of ch5D12. Patients were diagnosed as RA (n ¼ 17) and RARS (n ¼ 4) according to FAB, and as RCMD (n ¼ 14), 5qÀ (n ¼ 2), MDS-u (n ¼ 1), RCMD-RS (n ¼ 4) according to WHO. Significant more CFU-GM and BFU-E grew in the presence of ch5D12 compared with cultures without 
Plots show results of Mann-Whitney U-tests to compare means of controls and patients. MDS, myelodysplastic syndromes; PB, peripheral blood; RA, refractory anemia; RARS, RA with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; SSC, side scatter.
Activated monocytes in myelodysplastic syndromes
S Meers et al ch5D12 (see Figure 4a ). To prove that this effect was monocytedependent, we also added ch5D12 to cultures of BMMNC depleted of CD14 þ cells by MACS columns. The presence of ch5D12 did not alter colony formation of CD14-depleted BMMNC, whereas ch5D12 increased colony production in the same samples in presence of all BMMNC (see Figure 4b) . We did not observe a significant effect of ch5D12 on CFU-GM and BFU-E colony number in BMMNC cultures of nine healthy controls (see Figure 4c ). To further substantiate that CD40-CD40L interaction may affect hematopoietic progenitors, we examined whether a correlation exists between the number of CD40L þ T helper cells or CD40 þ monocytes within BMMNC. We demonstrated an inverse correlation between the umber of BFU-E and the percentage of CD40L þ T helper cells in that particular patient group (r ¼ À0.61, P ¼ 0.03). Although there was also a trend for lower numbers of CFU-GM with increasing percentage of CD40 þ monocytes, this was not significant (r ¼ À0.46, P ¼ 0.07).
Correlation between expression of activation markers by monocytes and clinical characteristics
We evaluated whether there was a correlation between the expression of CD40 and CD40L, on CD14 þ monocytes and T helper lymphocytes, respectively, and disease or patient characteristics. First, we correlated expression levels with hematological values. We observed a negative correlation between absolute neutrophil count (ANC) and the percentage of circulating CD80 þ monocytes, not only in the PB group (r ¼ À0.32, P ¼ 0.02), but also in the BM group where ANC at the time of BM sampling was lower with increasing BM CD80 þ monocytes (r ¼ À0.59, P ¼ 0.009). Of note, in healthy donors, we also found an inverse correlation between ANC and the percentage of CD80 þ monocytes (r ¼ À0.49, Po0.01). Although this type of analysis does not allow demonstration of a causal relationship, this suggests that activation of monocytes can be related to lower ANC values, irrespective of disease status. We found no correlation between blast-percentage and the expression of these surface molecules. Serum concentrations of CRP were generally low and independent of expression of co-stimulatory molecules. Clinical signs or a history of autoimmunity was observed in five patients, but did not relate to the level of CD40, CD80 or CD86 expression. Subsequently, we determined if expression of these markers on monocytes correlated with disease status according to the FAB subtype, WHO subtype, International Prognostic Scoring System score, cytogenetics, gender or previous treatment. We found no differences between RA and RARS patients. Interestingly, we found that patients with the karyotypic abnormality trisomy 8 had the highest level of circulating CD40 þ monocytes There were no differences between treatment-naïve patients, transfused patients or patients receiving other MDS treatments, with regards to the expression of activation markers by monocytes. Finally, we separated patients into two groups based on the percentage CD40-expressing monocytes, using the highest value of CD40-expressing monocytes found in the control group as the cut-off value (6.4%): one group of patients with o6.4% CD40 þ monocytes, and a group of patients with 46.4% CD40 þ monocytes. High levels of CD40 þ monocytes coincided with a higher International Prognostic Scoring System score, intermediate and poor cytogenetic risk score, age below 60 years and presence of trisomy 8 (see Table 2 and Figures 5a  and b) . The latter two factors have been identified in multivariate analyses as being independent factors predictive of response to immunosuppressive therapy. Of note, patients with favorable karyotypic abnormalities (three patients with del(5q), two patients with del(20q) and two men with -Y) had low expression of CD40 on their circulating monocytes.
Control MDS
Discussion
Cytopenia is the presenting symptom of most patients with MDS and is the leading cause of morbidity and mortality. The presence of abnormal clonal progenitor cells plays a pivotal role in the development of marrow failure, but immune enhancing mechanisms contribute to a variable extent to this process. Most previous work has focused on the role of lymphocytes in this process. Autologous T cells inhibit growth of progenitor cells in MDS, 2, 3 and this effect can disappear after successful treatment with ATG. 2 A role of immune-mediated suppression of hematopoiesis has been most extensively defined in trisomy 8 MDS. Consistent with what was shown for the general population of MDS patients, 4, 6, 7 Sloand et al. 5 have demonstrated that expanded clonal populations of T cells can be found in all patients with trisomy 8. In addition, they showed that the suppressive action of autologous T cells in these patients is restricted to CD8 þ T cells with this specific clonotype. Notwithstanding these insights, it is still unknown how immune-mediated mechanisms contribute to the pancytopenia seen in MDS. In trisomy 8 patients responding to immunosuppressive therapy, the number of progenitor cells with an extra chromosome 8 increases, 5 suggesting that the expanded clonal population of T lymphocytes in these patients controls the growth of genetically abnormal hematopoietic progenitors. Marrow failure associated with this immune response that appears to be directed specifically at the malignant clone, must therefore come from bystander effects on remaining normal hematopoietic cells. It is not known which factors cause this bystander phenomenon, and several mechanisms have been suggested for this inhibition of normal progenitor cells by T cells: 5 release of cytokines by activated T cells; 28 crossrecognition of targets through molecular mimicry; epitope spreading. 29 The aim of this study was to investigate the possible role of monocytes in this immune-mediated process. Monocytes are the main source of TNF-a production, which can suppress hemotopoiesis. 15 Activated T cells can induce TNF-a production by monocytes via CD40-CD40L interactions. The CD40 receptor is a 45-50 kDa type I phosphoprotein that is a member of the TNF receptor superfamily. It has been demonstrated that monocytes express low levels of CD40, 30 but expression of the CD40 gene is induced upon activation, which is most pronounced by stimulation with IFN-g. 27 Besides production of TNF-a, CD40 ligation also results in the secretion of other pro-inflammatory cytokines and chemokines such as IL-1, IL-6, IL-8, IL-10, IL-12 and macrophage-inflammatory protein-1a. 18, 19 In addition, ligation of CD40 by CD40L, present on T helper cells, promotes upregulation of co-stimulatory molecules (CD40, CD80, CD86, MHC class II molecules) and FasL. CD40L is transiently expressed on activated T helper cells and has been shown to be present on PB T helper cells in several autoimmune conditions. Since lymphocytes in MDS have been found to have an activated phenotype, 7,31 this pathway could be responsible for activation of monocytes in BM of MDS patients, for production of TNF-a and subsequent suppression of hematopoiesis.
Here, we demonstrated a role of CD40-CD40L interactions in the pathogenesis of MDS-related marrow failure. First of all, we have shown in a large group of 57 predominantly low-risk untreated patients, that significantly more PB CD14 þ monocytes express CD40. In addition, significantly more PB T helper cells express CD40L in MDS patients, and expression of CD40L on T lymphocytes highly correlated with CD40 expression of CD14 þ monocytes. Overexpression of CD40 and CD40L was also observed in BM samples, where lymphocytes and monocytes are thought to exert their function. Besides measurement of expression levels of CD40 and CD40L, we also analyzed the in vitro effects of stimulation and inhibition of this pathway on TNF-a production and proliferation and differentiation of Activated monocytes in myelodysplastic syndromes S Meers et al hematopoietic progenitors. Ligation of CD40 on MDS monocytes using the agonist anti-CD40 mAb resulted in increased TNF-a production compared to controls. To the best of our knowledge, this is the first report demonstrating different behavior of MDS monocytes with regards to TNF-a production. In our series, TNF-a production was similar between MDS and normal monocytes stimulated with LPS, consistent with previous reports by others. 17 Increased surface expression of the CD40 receptor on MDS monocytes could account for this different behavior, but also activation of different downstream pathways might be responsible. 30 This remains to be explored. In addition, we analyzed the effects of inhibiting this pathway in colony formation assays, using the monoclonal antibody ch5D12, which is an antagonist chimeric anti-human CD40 antibody that has been shown to be effective in the therapy of inflammatory bowel disease 22 and non-human primate models of autoimmune encephalomyelitis. 24 In the presence of ch5D12, the number of BFU-E and CFU-GM significantly increased in cultures of MDS BMMNC, but not following depletion of CD14 þ monocytes prior to initiating the colonyforming assay. This suggests that the inhibitory effects of monocytes on hematopoiesis can be overcome by antagonizing the CD40 receptor on these monocytes using ch5D12. Together with the observation that the number of BFU-E inversely correlates with the percentage of CD40L þ T helper cells, this suggests that the inhibitory effect of lymphocytes on hematopoiesis can be partially attributed to additional cytokine release from monocytes. However, it is still unclear which cytokines are responsible for this. Because the TNF-a concentrations in our BM cultures were very low, we were unable to observe downregulation of TNF-a levels in presence of ch5D12 (data not shown).
Taken together, these observations could have both diagnostic as well as therapeutic values. First, we have shown that expression of CD40 by MDS monocytes could serve as a marker for an ongoing immune attack inside the BM. Although CD40 expression on circulating monocytes is increased in patients with severe sepsis, 32 a systemic inflammatory response is not likely to be responsible for our results. CRP levels were low and did not correlate with expression of CD40 on CD14 þ cells. In addition, patients with a recent history of infection were excluded from this study. The use of CD40 as a marker of immunological activity in the marrow is additionally supported by the observation that age below 60 years and trisomy 8 coincide with high CD40 expression. Both factors have been identified as the strongest predictors for response to immunosuppressive therapy in MDS 14, 33 and therefore immune mechanisms play a particular important role in these patients.
But, the question remains if monocytes just mirror the ongoing immune attack or are actively contributing to the process of marrow failure. The strongest argument to support this is that inhibition of CD40 signaling on monocytes results in increased BFU-E and CFU-GM formation. Furthermore, the number of CFU-GM inversely correlated with the percentage of CD40 þ
CD14
þ cells, even though this did not reach statistical significance. In addition, increased percentages of activated Patients are grouped into a 'high' and 'low' group, using the highest measured value in the control group as cut-off point (6.4%). monocytes coincided with decreased ANC, an observation made in the 57 blood samples, but also independently in 20 BM samples that were obtained from different patients. The last observation was also made in PB from the age-matched controls, therefore suggesting that it is not specific for MDS, although caution should be exerted as coincidence does not prove a causal relation.
Previous studies have demonstrated that CD8 þ T cells have an activated phenotype in MDS patients. 7, 31 Here, we show that also CD4 þ T cells are activated in patients and demonstrate their possible involvement in MDS pathogenesis through CD40-CD40L interactions as CD40L expression by T helper cells coincided with CD40 expression by monocytes. In addition, we observed that the number of BFU-E in MDS BMMNC cultures significantly decreased with increasing CD40L expression by T helper cells. The high percentage of circulating CD40L-expressing T helper cells is intriguing. It indicates that CD40L expression is either increased or stabilized in MDS. The increased CD40L expression may be involved through antigen-presenting cells in the induction of the suppressive CD8 clonotype, but this also warrants further investigation.
Apart from their diagnostic value, our observations could also have therapeutic perspectives as antagonizing the CD40-CD40L interaction could be an attractive way to treat MDSrelated cytopenia. Monoclonal antibodies against CD40 are currently under investigation for their use in various hematological disease, such as multiple myeloma 34, 35 and non-Hodgkin's lymphoma. 36 The mode of action of these antibodies relies on antibody-dependent cell-mediated cytotoxicity 37 and by a direct apoptotic effect on malignant cells. 34 In other malignancies, activation of monocytes with agonist anti-CD40 mAb has been shown to inhibit tumor growth. 38 In MDS, however, the therapeutic value is to be expected by tapering the immune response and hence limiting collateral damage on normal progenitors to improve blood counts. For this reason, inhibition rather than stimulation of the CD40-CD40L pathways seems therapeutically relevant in MDS. Since clinical development of all other antagonist anti-human CD40L antibodies have been terminated due to thrombotic events, the antagonist anti-CD40 ch5D12 described here is the only current option to target inhibition of CD40-CD40L in human pathologies including MDS.
